Off Patent
March 2026

Pradaxa

dabigatran etexilate mesylate

Boehringer Ingelheim Pharmaceuticals Inc

Pellets (oral) · NDA 214358

Last listed protection ended
March 7, 2026

The FDA listed 1 patent for Pradaxa, and this is the day the last one ended. It is not the date a generic goes on sale.

Patents and exclusivities

  1. Ended
    Patent 7,932,273
    Claims the drug substance and the drug product
  2. Ended
    Patent 7,932,273
    Pediatric extension: six more months